Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 3/2010

01-09-2010

Pancreatic β-cell KATP channels: Hypoglycaemia and hyperglycaemia

Authors: Kate Bennett, Chela James, Khalid Hussain

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2010

Login to get access

Abstract

The pancreatic β-cell ATP-sensitive K+ channel (KATP channel) plays a critical role in glucose homeostasis by linking glucose metabolism to electrical excitability and insulin secretion. Changes in the intracellular ratio of ATP/ADP mediate the metabolic regulation of channel activity. The β-cell KATP channel is a hetero-octameric complex composed of two types of subunits: four inward-rectifying potassium channel pore-forming (Kir6.2) subunits and four high-affinity sulfonylurea receptor 1 (SUR1) subunits. Kir6.2 and SUR1 are encoded by the genes KCNJ11 and ABCC8, respectively. Mutations in these genes can result in congenital hyperinsulinism and permanent neonatal diabetes. This review highlights the important role of the β-cell KATP channel in glucose physiology and provides an introduction to some of the other review articles in this special edition of the Reviews in Endocrine and Metabolic Disorders.
Literature
1.
Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science. 1998;280(5360):69–77.CrossRefPubMed
2.
Kuo A, Gulbis JM, Antcliff JF, Rahman T, Lowe ED, Zimmer J, et al. Crystal structure of the potassium channel KirBac1.1 in the closed state. Science. 2003;300(5627):1922–6.CrossRefPubMed
3.
Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 1983;305(5930):147–8.
4.
Ashcroft FM. Adenosine 5′-triphosphate-sensitive potassium channels. Annu Rev Neurosci. 1988;11:97–118.CrossRefPubMed
5.
Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature. 2006;440(7083):470–6.CrossRefPubMed
6.
Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52(5):1147–54.CrossRefPubMed
7.
Yokoshiki H, Sunagawa M, Seki T, Sperelakis N. ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol. 1998;274(1 Pt 1):C25–37.PubMed
8.
Miki T, Seino S. Roles of KATP channels as metabolic sensors in acute metabolic changes. J Mol Cell Cardiol. 2005;38(6):917–25.CrossRefPubMed
9.
Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes. 2005;54(9):2503–13.CrossRefPubMed
10.
Tarasov A, Dusonchet J, Ashcroft F. Metabolic regulation of the pancreatic beta-cell ATP-sensitive K+ channel: a pas de deux. Diabetes. 2004;53 Suppl 3:S113–22.CrossRefPubMed
11.
Akrouh A, Halcomb SE, Nichols CG, Sala-Rabanal M. Molecular biology of K(ATP) channels and implications for health and disease. IUBMB Life. 2009;61(10):971–8.CrossRefPubMed
12.
Shyng S, Nichols CG. Octameric stoichiometry of the KATP channel complex. J Gen Physiol. 1997;110(6):655–64.CrossRefPubMed
13.
Du X, Zhang H, Lopes C, Mirshahi T, Rohacs T, Logothetis DE. Characteristic interactions with phosphatidylinositol 4, 5-bisphosphate determine regulation of kir channels by diverse modulators. J Biol Chem. 2004;279(36):37271–81.CrossRefPubMed
14.
15.
Lu Z. Mechanism of rectification in inward-rectifier K+ channels. Annu Rev Physiol. 2004;66:103–29.CrossRefPubMed
16.
Clarke OB, Caputo AT, Hill AP, Vandenberg JI, Smith BJ, Gulbis JM. Domain reorientation and rotation of an intracellular assembly regulate conduction in Kir potassium channels. Cell. 2010;141(6):1018–29.CrossRefPubMed
17.
Hilgemann DW, Ball R. Regulation of cardiac Na+, Ca2+ exchange and KATP potassium channels by PIP2. Science. 1996;273(5277):956–9.CrossRefPubMed
18.
Tucker SJ, Gribble FM, Proks P, Trapp S, Ryder TJ, Haug T, et al. Molecular determinants of KATP channel inhibition by ATP. EMBO J. 1998;17(12):3290–6.CrossRefPubMed
19.
MacGregor GG, Dong K, Vanoye CG, Tang L, Giebisch G, Hebert SC. Nucleotides and phospholipids compete for binding to the C terminus of KATP channels. Proc Natl Acad Sci USA. 2002;99(5):2726–31.CrossRefPubMed
20.
Antcliff JF, Haider S, Proks P, Sansom MS, Ashcroft FM. Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit. EMBO J. 2005;24(2):229–39.CrossRefPubMed
21.
Aittoniemi J, Fotinou C, Craig TJ, de Wet H, Proks P, Ashcroft FM. Review. SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator. Philos Trans R Soc Lond B Biol Sci. 2009;364(1514):257–67.CrossRefPubMed
22.
Higgins CF. ABC transporters: physiology, structure and mechanism—an overview. Res Microbiol. 2001;152(3–4):205–10.
23.
Conti LR, Radeke CM, Shyng SL, Vandenberg CA. Transmembrane topology of the sulfonylurea receptor SUR1. J Biol Chem. 2001;276(44):41270–8.CrossRefPubMed
24.
Hollenstein K, Dawson RJ, Locher KP. Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol. 2007;17(4):412–8.CrossRefPubMed
25.
Schwappach B, Zerangue N, Jan YN, Jan LY. Molecular basis for K(ATP) assembly: transmembrane interactions mediate association of a K+ channel with an ABC transporter. Neuron. 2000;26(1):155–67.CrossRefPubMed
26.
Tucker SJ, Gribble FM, Zhao C, Trapp S, Ashcroft FM. Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. Nature. 1997;387(6629):179–83.CrossRefPubMed
27.
Zerangue N, Schwappach B, Jan YN, Jan LY. A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K(ATP) channels. Neuron. 1999;22(3):537–48.CrossRefPubMed
28.
Zerangue N, Malan MJ, Fried SR, Dazin PF, Jan YN, Jan LY, et al. Analysis of endoplasmic reticulum trafficking signals by combinatorial screening in mammalian cells. Proc Natl Acad Sci USA. 2001;98(5):2431–6.CrossRefPubMed
29.
Crane A, Aguilar-Bryan L. Assembly, maturation, and turnover of K(ATP) channel subunits. J Biol Chem. 2004;279(10):9080–90.CrossRefPubMed
30.
Dabrowski M, Tarasov A, Ashcroft FM. Mapping the architecture of the ATP-binding site of the KATP channel subunit Kir6.2. J Physiol. 2004;557(Pt 2):347–54.CrossRefPubMed
31.
Mankouri J, Taneja TK, Smith AJ, Ponnambalam S, Sivaprasadarao A. Kir6.2 mutations causing neonatal diabetes prevent endocytosis of ATP-sensitive potassium channels. EMBO J. 2006;25(17):4142–51.CrossRefPubMed
32.
Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes. 2004;53(10):2713–8.CrossRefPubMed
33.
Vaxillaire M, Populaire C, Busiah K, Cavé H, Gloyn AL, Hattersley AT, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes. 2004;53(10):2719–22.CrossRefPubMed
34.
Clark R, Proks P. ATP-sensitive potassium channels in health and disease. Adv Exp Med Biol. 2010;654:165–92.CrossRefPubMed
35.
Flanagan SE, Clauin S, Bellanné-Chantelot C, de Lonlay P, Harries LW, Gloyn AL, et al. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat. 2009;30(2):170–80.CrossRefPubMed
36.
James C, Kapoor RR, Ismail D, Hussain K. The genetic basis of congenital hyperinsulinism. J Med Genet. 2009;46(5):289–99.CrossRefPubMed
37.
Tornovsky S, Crane A, Cosgrove KE, Hussain K, Lavie J, Heyman M, et al. Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and evidence for additional locus heterogeneity. J Clin Endocrinol Metab. 2004;89(12):6224–34.CrossRefPubMed
38.
Marthinet E, Bloc A, Oka Y, Tanizawa Y, Wehrle-Haller B, Bancila V, et al. Severe congenital hyperinsulinism caused by a mutation in the Kir6.2 subunit of the adenosine triphosphate-sensitive potassium channel impairing trafficking and function. J Clin Endocrinol Metab. 2005;90(9):5401–6.CrossRefPubMed
39.
Taschenberger G, Mougey A, Shen S, Lester LB, LaFranchi S, Shyng S. Identification of a familial hyperinsulinism-causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of KATP channels. J Biol Chem. 2002;277(19):17139–46.CrossRefPubMed
40.
Sharma N, Crane A, Clement JP, Gonzalez G, Babenko AP, Bryan J, et al. The C terminus of SUR1 is required for trafficking of KATP channels. J Biol Chem. 1999;274(29):20628–32.CrossRefPubMed
41.
Huopio H, Shyng S, Otonkoski T, Nichols CG. K(ATP) channels and insulin secretion disorders. Am J Physiol Endocrinol Metab. 2002;283(2):E207–16.PubMed
42.
Nestorowicz A, Inagaki N, Gonoi T, Schoor KP, Wilson BA, Glaser B, et al. A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. Diabetes. 1997;46(11):1743–8.CrossRefPubMed
43.
Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko HL, Rahier J, et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest. 2000;106(7):897–906.CrossRefPubMed
44.
Pinney SE, MacMullen C, Becker S, Lin Y, Hanna C, Thornton P, et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest. 2008;118(8):2877–86.CrossRefPubMed
45.
Rahier J, Guiot Y, Sempoux C. Persistent hyperinsulinaemic hypoglycaemia of infancy: a heterogeneous syndrome unrelated to nesidioblastosis. Arch Dis Child Fetal Neonatal Ed. 2000;82(2):F108–12.CrossRefPubMed
46.
Hussain K, Flanagan SE, Smith VV, Ashworth M, Day M, Pierro A, et al. An ABCC8 gene mutation and mosaic uniparental isodisomy resulting in atypical diffuse congenital hyperinsulinism. Diabetes. 2008;57(1):259–63.CrossRefPubMed
47.
Verkarre V, Fournet JC, de Lonlay P, Gross-Morand MS, Devillers M, Rahier J, et al. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest. 1998;102(7):1286–91.CrossRefPubMed
48.
Damaj L, le Lorch M, Verkarre V, Werl C, Hubert L, Nihoul-Fékété C, et al. Chromosome 11p15 paternal isodisomy in focal forms of neonatal hyperinsulinism. J Clin Endocrinol Metab. 2008;93(12):4941–7.CrossRefPubMed
49.
Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C. Parental genomic imprinting of the human IGF2 gene. Nat Genet. 1993;4(1):98–101.CrossRefPubMed
50.
51.
Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, et al. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms’ tumors. Hum Mol Genet. 1996;5(6):783–8.CrossRefPubMed
52.
Fournet JC, Mayaud C, de Lonlay P, Gross-Morand MS, Verkarre V, Castanet M, et al. Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11. Am J Pathol. 2001;158(6):2177–84.PubMed
53.
Leibowitz G, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. J Clin Endocrinol Metab. 1995;80(2):386–92.CrossRefPubMed
54.
Adzick NS, Thornton PS, Stanley CA, Kaye RD, Ruchelli E. A multidisciplinary approach to the focal form of congenital hyperinsulinism leads to successful treatment by partial pancreatectomy. J Pediatr Surg. 2004;39(3):270–5.CrossRefPubMed
55.
Ribeiro M, De Lonlay P, Delzescaux T, Boddaert N, Jaubert F, Bourgeois S, et al. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA. J Nucl Med. 2005;46(4):560–6.PubMed
56.
Otonkoski T, Näntö-Salonen K, Seppänen M, Veijola R, Huopio H, Hussain K, et al. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes. 2006;55(1):13–8.CrossRefPubMed
57.
Peranteau WH, Ganguly A, Steinmuller L, Thornton P, Johnson MP, Howell LJ, et al. Prenatal diagnosis and postnatal management of diffuse congenital hyperinsulinism: a case report. Fetal Diagn Ther. 2006;21(6):515–8.CrossRefPubMed
58.
Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350(18):1838–49.CrossRefPubMed
59.
Edghill EL, Gloyn AL, Goriely A, Harries LW, Flanagan SE, Rankin J, et al. Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. J Clin Endocrinol Metab. 2007;92(5):1773–7.CrossRefPubMed
60.
Ellard S, Flanagan SE, Girard CA, Patch A, Harries LW, Parrish A, et al. Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet. 2007;81(2):375–82.CrossRefPubMed
61.
Koster JC, Marshall BA, Ensor N, Corbett JA, Nichols CG. Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. Cell. 2000;100(6):645–54.CrossRefPubMed
62.
Gloyn AL, Reimann F, Girard C, Edghill EL, Proks P, Pearson ER, et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet. 2005;14(7):925–34.CrossRefPubMed
63.
Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355(5):456–66.CrossRefPubMed
64.
Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci USA. 2004;101(50):17539–44.CrossRefPubMed
65.
Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52(2):568–72.CrossRefPubMed
66.
Schwanstecher C, Neugebauer B, Schulz M, Schwanstecher M. The common single nucleotide polymorphism E23K in K(IR)6.2 sensitizes pancreatic beta-cell ATP-sensitive potassium channels toward activation through nucleoside diphosphates. Diabetes. 2002;51 Suppl 3:S363–7.CrossRefPubMed
67.
Seino S, Iwanaga T, Nagashima K, Miki T. Diverse roles of K(ATP) channels learned from Kir6.2 genetically engineered mice. Diabetes. 2000;49(3):311–8.CrossRefPubMed
68.
Shimomura K, Hörster F, de Wet H, Flanagan SE, Ellard S, Hattersley AT, et al. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology. 2007;69(13):1342–9.CrossRefPubMed
Metadata
Title
Pancreatic β-cell KATP channels: Hypoglycaemia and hyperglycaemia
Authors
Kate Bennett
Chela James
Khalid Hussain
Publication date
01-09-2010
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 3/2010
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-010-9144-2

Other articles of this Issue 3/2010

Reviews in Endocrine and Metabolic Disorders 3/2010 Go to the issue

OriginalPaper

Role of 18F-DOPA PET/CT imaging in congenital hyperinsulinism

OriginalPaper

6q24 transient neonatal diabetes

OriginalPaper

Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene

OriginalPaper

The hyperinsulinism/hyperammonemia syndrome

OriginalPaper

Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11

OriginalPaper

Congenital Hyperinsulinism due to mutations in HNF4A and HADH
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits